Trademark: 90354435
Word
ENIGMA
Status
Pending
Status Code
734
Status Date
Friday, May 3, 2024
Serial Number
90354435
Mark Type
4
Filing Date
Wednesday, December 2, 2020
Published for Opposition
Tuesday, September 28, 2021

Trademark Owner History
CANADIAN NEUTRICEUTICAL HEALTH INC. - Owner At Publication

Classifications
5 Pharmaceutical preparations, namely, antivirals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Analgesic and muscle relaxant pharmaceutical preparations; Antimicrobial preservatives for pharmaceuticals; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, injectable contraceptives; Potassium preparations for pharmaceutical purposes; Pharmaceuticals, namely, psychotropics; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, antihelmintics; Pharmaceutical antitussive-cold preparations; Ocular pharmaceuticals; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations, namely, anticoagulants; Alcohol for pharmaceutical purposes; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Antibacterial pharmaceuticals; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Cardiovascular pharmaceuticals; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for use in oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for treating halitosis; Pharmaceutical preparations for treating hypoglycemia; Pharmaceutical preparations for the treatment of bone fractures; Pharmaceutical preparations for the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for treating allergic rhinitis; Pharmaceutical preparations for treating asthma; Pharmaceutical products for the treatment of cancer

Trademark Events
Dec 5, 2020
New Application Entered
May 19, 2021
Assigned To Examiner
Feb 8, 2021
New Application Office Supplied Data Entered
Aug 12, 2021
Teas/Email Correspondence Entered
May 28, 2021
Non-Final Action E-Mailed
May 28, 2021
Notification Of Non-Final Action E-Mailed
May 28, 2021
Non-Final Action Written
Aug 11, 2021
Correspondence Received In Law Office
Aug 11, 2021
Teas Response To Office Action Received
Aug 25, 2021
Examiners Amendment E-Mailed
Aug 25, 2021
Notification Of Examiners Amendment E-Mailed
Aug 25, 2021
Examiner's Amendment Entered
Aug 25, 2021
Examiners Amendment -Written
Aug 25, 2021
Approved For Pub - Principal Register
Sep 8, 2021
Notification Of Notice Of Publication E-Mailed
Sep 28, 2021
Published For Opposition
Sep 28, 2021
Official Gazette Publication Confirmation E-Mailed
Nov 23, 2021
Noa E-Mailed - Sou Required From Applicant
Apr 28, 2022
Sou Extension 1 Filed
Apr 28, 2022
Sou Teas Extension Received
Apr 28, 2022
Sou Extension 1 Granted
May 2, 2023
Sou Teas Extension Received
May 2, 2023
Sou Extension 3 Filed
Apr 30, 2022
Notice Of Approval Of Extension Request E-Mailed
Nov 10, 2022
Sou Teas Extension Received
Nov 10, 2022
Sou Extension 2 Filed
Nov 10, 2022
Sou Extension 2 Granted
Nov 12, 2022
Notice Of Approval Of Extension Request E-Mailed
May 2, 2023
Sou Extension 3 Granted
May 4, 2023
Notice Of Approval Of Extension Request E-Mailed
May 3, 2024
Sou Extension 5 Filed
May 3, 2024
Sou Teas Extension Received
May 3, 2024
Sou Extension 5 Granted
May 4, 2024
Notice Of Approval Of Extension Request E-Mailed
Nov 25, 2023
Notice Of Approval Of Extension Request E-Mailed
Nov 23, 2023
Sou Teas Extension Received
Nov 23, 2023
Sou Extension 4 Filed
Nov 23, 2023
Sou Extension 4 Granted

Trademark Alertz updated from USPTO on 2030-01-24